Xenetic Biosciences Inc Stock Price, News & Analysis

Xenetic Biosciences (NASDAQ:XBIO) executed a 4-month extension of its R&D collaboration with Scripps Research and Dr. Alexey Stepanov effective November 1, 2025 to advance its systemic DNase I program (XBIO-015) in combination with CAR-T therapies.

Preclinical studies in lymphoma, metastatic melanoma and leukemia models reported that co-administration of DNase I with CAR-T cells reduced tumor burden, decreased metastatic lesions, increased CAR-T and endogenous T-cell tumor infiltration, and extended survival versus CAR-T monotherapy. Xenetic says the program has progressed from proof-of-concept to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial targeting pancreatic carcinoma and other advanced solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) reported third quarter 2025 results on November 13, 2025, highlighting continued preclinical progress on its systemic DNase I oncology program and partnerships to support investigator‑initiated studies.

Key financials: Q3 net loss ~$0.5M; R&D +105.6% to ~$0.8M; Revenue +67.2% to ~$1.0M driven by Takeda sublicense royalties; quarter‑end cash ~$4.1M and subsequent October 2025 underwritten offering net proceeds of ~$3.9M to extend runway toward IND preparation and Phase 1 initiation.

Xenetic Biosciences (NASDAQ:XBIO) priced an underwritten offering of 735,000 shares of common stock at $6.12 per share for gross proceeds of approximately $4.5 million. The offering is expected to close on or about October 14, 2025, subject to customary closing conditions, with Canaccord Genuity as sole bookrunner.

All shares are being offered by Xenetic and proceeds are intended for working capital and general corporate purposes. The offering is made under a Form S-3 shelf registration declared effective November 1, 2024 (File No. 333-282756); a final prospectus supplement will be filed with the SEC.

Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2025 financial results, highlighting key developments in its immuno-oncology programs. The company has expanded its strategic partnership with The Scripps Research Institute to advance DNase I combination therapy with CAR T-cells. Through collaboration with PeriNess, Xenetic initiated clinical studies exploring DNase I combinations with anti-CD19 CAR T cells for lymphoma and with FOLFIRINOX for pancreatic cancer.

Financial results showed a net loss of $0.7 million for Q2 2025, with decreased R&D expenses of $0.7 million (down 29.7% YoY) and reduced G&A expenses of $0.7 million (down 41.8% YoY). The company maintained a cash position of $4.8 million at quarter-end.

Xenetic Biosciences (NASDAQ:XBIO) announced that its collaboration partner PeriNess has entered into a Clinical Study Agreement to evaluate DNase I in combination with anti-CD19 CAR T cells for treating large B cell lymphoma. The study will be conducted at Tel Aviv Sourasky Medical Center under Dr. Ron Ram's leadership.

The study aims to assess the safety and efficacy of DNase I as an adjuvant therapy with CAR T treatment. Secondary objectives include measuring complete response rate, duration of response, and overall survival. Preclinical studies have shown that DNase I co-administration with anti-CD19 CAR T cells significantly reduced tumor burden and improved survival compared to CAR T cell monotherapy.

This development follows Xenetic's December 2024 agreement with PeriNess for investigating DNase I as an adjunctive treatment in pancreatic carcinoma and other solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) has expanded its research collaboration with The Scripps Research Institute to advance its DNase platform development. The company's systemic DNase I candidate, XBIO-015, is being developed in combination with CAR-T cell therapy for both hematologic and solid tumors.

Studies have demonstrated that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to CAR-T cell therapy alone. The research program will now include additional models of lymphoma and leukemia to further validate these findings.

The DNase-based platform targets neutrophil extracellular traps (NETs) in the tumor microenvironment, with preclinical data showing improved efficacy of various cancer treatments. The company is advancing towards Phase 1 clinical development for pancreatic carcinoma and other advanced solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) announced that its collaboration partner PeriNess has begun patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study evaluates systemic DNase I in combination with FOLFIRINOX for first-line treatment of unresectable, locally advanced or metastatic pancreatic cancer.

The study, led by Dr. Abed Agbabrya, will assess safety, biomarker response, pharmacokinetics, and clinical activity of DNase I. Patients will receive intravenous DNase I infusions on Days 1 and 8 of 14-day cycles. The trial's effectiveness will be measured through Objective Response Rate (ORR) and Progression-Free Survival (PFS).

This initiative stems from a December 2024 Clinical Trial Services Agreement between Xenetic and PeriNess for exploring DNase as an adjunctive treatment in pancreatic carcinoma and other solid tumors.

Xenetic Biosciences (NASDAQ:XBIO) reported its Q1 2025 financial results, highlighting progress in its DNase-based technology development. The company recorded a net loss of $0.9 million with revenue increasing 16.1% to $0.6 million compared to Q1 2024. Operating expenses decreased by 13.7% to $1.5 million. The company maintains $5.2 million in cash. Key developments include a partnership with PeriNess Ltd. for clinical studies on DNase platform treating relapsed/refractory osteosarcoma and Ewing sarcoma. Xenetic is advancing towards Phase 1 clinical trials for pancreatic carcinoma treatment, with completed preliminary studies on DNase I combinations with chemotherapy, immuno-therapies, and CAR-T therapy in colorectal cancer models.

Xenetic Biosciences (NASDAQ:XBIO) has released a Virtual Investor segment featuring Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development. The segment focuses on the company's recent poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.

The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', highlights preclinical data in the company's immune-oncology program targeting difficult to treat cancers.